AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
AAPL   375.51 (+0.44%)
FB   243.93 (+1.52%)
AMZN   3,039.08 (-0.59%)
NVDA   398.47 (+1.25%)
TSLA   1,396.99 (+1.85%)
ACB   12.47 (+2.38%)
GILD   76.66 (-0.13%)
BAC   23.08 (-2.45%)
NFLX   494.21 (+0.08%)
BA   182.14 (-3.07%)
Log in

NASDAQ:IMMUImmunomedics Stock Price, Forecast & News

$41.13
+0.50 (+1.23 %)
(As of 07/7/2020 02:02 PM ET)
Add
Compare
Today's Range
$40.20
Now: $41.13
$41.66
50-Day Range
$30.18
MA: $33.89
$37.54
52-Week Range
$8.80
Now: $41.13
$41.40
Volume124,960 shs
Average Volume4.24 million shs
Market Capitalization$9.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.36
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Read More
Immunomedics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.89 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$290,000.00
Price / Sales32,747.99
Book Value$1.38 per share

Profitability

Net Income$-357,190,000.00

Miscellaneous

Employees346
Market Cap$9.50 billion
Next Earnings DateN/A
OptionableOptionable

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

How has Immunomedics' stock been impacted by COVID-19 (Coronavirus)?

Immunomedics' stock was trading at $13.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMMU shares have increased by 207.0% and is now trading at $41.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Immunomedics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunomedics.

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.46) by $0.02. During the same quarter last year, the firm earned ($0.46) EPS. View Immunomedics' earnings history.

What price target have analysts set for IMMU?

13 brokerages have issued 1 year price targets for Immunomedics' shares. Their forecasts range from $22.00 to $56.00. On average, they anticipate Immunomedics' stock price to reach $37.38 in the next twelve months. This suggests that the stock has a possible downside of 9.0%. View analysts' price targets for Immunomedics.

What are Wall Street analysts saying about Immunomedics stock?

Here are some recent quotes from research analysts about Immunomedics stock:
  • 1. According to Zacks Investment Research, "Immunomedics reported a narrower-than-expected loss in the first quarter. The company got a significant boost with the recent FDA approval for its lead drug, Trodelvy, an antibody-drug conjugate (ADC), for the treatment of patients with mTNBC. The commercial launch of the drug is underway. The successful commercialization of the drug will bring in sales for the company. Meanwhile, Trodelvy is being evaluated in several label expansion studies, including earlier-line settings for breast cancer and other cancer indications. A late-stage study on the candidate was recently halted due to its compelling efficacy. Immunomedics is also evaluating acituzumab in other cancer types. A potential label expansion of the drug will further boost growth prospects. However, competition is stiff from bigwigs in the market. Pipeline setbacks will also weigh on shares." (6/30/2020)
  • 2. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019)

Has Immunomedics been receiving favorable news coverage?

News stories about IMMU stock have been trending negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a news impact score of -2.1 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Immunomedics.

Who are some of Immunomedics' key competitors?

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Seattle Genetics (SGEN), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Micron Technology (MU), ImmunoGen (IMGN), Gilead Sciences (GILD), Netflix (NFLX), Novavax (NVAX) and Advanced Micro Devices (AMD).

Who are Immunomedics' key executives?

Immunomedics' management team includes the following people:
  • Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
  • Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
  • Mr. Scott A. Canute MBA, Exec. Director (Age 58)
  • Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
  • Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Fulton Bank N. A. (0.00%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc and Bryan Ball. View institutional ownership trends for Immunomedics.

Which major investors are buying Immunomedics stock?

IMMU stock was acquired by a variety of institutional investors in the last quarter, including Fulton Bank N. A.. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, and Bryan Ball. View insider buying and selling activity for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $41.08.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $9.49 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.